Lv1
50 积分 2025-04-01 加入
Sugemalimab: First Approval
4天前
已完结
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
1个月前
已完结
Recent Advances in Perioperative Immunotherapies in Lung Cancer
1个月前
已完结
Recent Advances in Perioperative Immunotherapies in Lung Cancer
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
3个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
3个月前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
3个月前
已关闭
Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial
3个月前
已完结
Nasopharyngeal carcinoma: an evolving paradigm
4个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody– drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
6个月前
已完结
皖公网安备34019202002308
